TIL Therapy Entering the Mainstream
TIL Therapy Entering the Mainstream
About this item
Full title
Author / Creator
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Melanomas have long been considered to be immunogenic tumors. Although anti–programmed death 1 (PD-1) therapy has been approved worldwide as first-line treatment, many patients do not benefit from it, so there is an important therapeutic gap. Adoptive cell therapy with tumor-infiltrating lymphocytes (TILs) was described in the 1980s by Rosenberg an...
Alternative Titles
Full title
TIL Therapy Entering the Mainstream
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_2753302556
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2753302556
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMe2214655
